NeurologyLive Friday 5 — June 19, 2020

June 19, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 19, 2020.

Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Peer Exchange: SPR1NT Trial of Onasemnogene Abeparvovec for SMA

The SPR1NT phase 3 clinical trial—pivotal in pushing the concept of newborn screening for SMA—assessing onasemnogene abeparvovec-xioi in children less than 6 weeks of age is discussed, as well as a recently released integrated safety report.

WATCH NOW

2: Progressive MS: The CMSC 2020 Whitaker Lecture

Scott Newsome, DO, MSCS, FAAN, president of CMSC, offers his perspective on the 2020 Whitaker Lecture from Peter Calabresi, MD.

WATCH NOW

3: AHS 2020: Erenumab Shows Sustainable Efficacy in Refractory Episodic Migraine

Over a 2-year stretch, change in monthly migraine days from the double-blind treatment period baseline was sustained in those treated with erenumab.

READ MORE

4: Insights: Gastroparesis and Uptake of Oral Medication for Parkinson Disease

Peter LeWitt, MD, offers an expert perspective on gastroparesis and its influence on the uptake of oral medication for Parkinson disease.

WATCH NOW

5: Intranasal DHE Meets Primary Objectives in Treatment of Acute Migraine

Impel NeuroPharma, the agent’s developer, is on target for submission of a new drug application for the treatment in the second half of 2020.

READ MORE